ACRS

Biotech's Role in Addressing the Pancreatic Cancer Emergency

Retrieved on: 
Thursday, March 14, 2024
Ovarian cancer, Immunotherapy, Patient, History, Lutetium (177Lu) oxodotreotide, IND, Cancer, NVS, NUVB, NCI, Novartis, Science, Colorectal cancer, Risk, American Cancer Society, FOLFIRINOX, PDAC, Pancreatic Cancer Action Network, Safety, Immune system, Interim, University, Translational research, Survival rate, Disease, Clinical professor, Associate, Tumor microenvironment, Death, TSX, Pancreatic cancer, Sunnybrook Health Sciences Centre, ACRS, FDA, DCP, Diagnosis, Entrepreneurship, Environment, Physician, Triple-negative breast cancer, Mortality, News, PROC, DDC, Hereditary nonpolyposis colorectal cancer, Optimism, ONC, Pharmaceutical industry

VANCOUVER, BC, March 14, 2024 /PRNewswire/ -- USA News Group - Known as one of the most deadly forms of cancer, pancreatic cancer still has the highest mortality rate of all major cancers today. However, researchers and the biotech sector are working diligently to improve the chances of those who receive this dire diagnosis. Recently, in late 2023, researchers at the Mayo Clinic made a discovery that advances knowledge of how pancreatic cancer spreads and identified a new potential therapeutic target along the way. With the American Cancer Society projecting a record year for new cancer cases in 2024, and Europe facing a pancreatic cancer emergency, it's important to focus on the advances being made in the biotech sector that are giving hope to patients and their families. Among the developers making gains include Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Novartis AG (NYSE: NVS), ImmunityBio, Inc. (NASDAQ: IBRX), Aclaris Therapeutics, Inc. (NASDAQ: ACRS), and Nuvation Bio Inc. (NYSE: NUVB). 

Key Points: 
  • There is a point of optimism to build upon, as the Pancreatic Cancer Action Network (PanCAN) has stated the five-year survival rate for pancreatic cancer has increased to 13% .
  • "Combining pelareorep with mFOLFIRINOX represents an expansion of our existing pancreatic cancer program and maximizes the potential of pelareorep-based combination therapies to benefit pancreatic cancer patients."
  • It will focus on patients with pancreatic cancer, HER2-negative metastatic breast cancer, metastatic castration-resistant prostate cancer (mCRPC), and platinum-resistant ovarian cancer (PROC).
  • Nuvation is already undergoing dosing in the Phase 1 monotherapy study of NUV-868 in solid tumors in patients with pancreatic cancer, ovarian cancer, metastatic castration-resistant prostate cancer (mCRPC), triple-negative breast cancer and other solid tumors.

Biotech's Role in Addressing the Pancreatic Cancer Emergency

Retrieved on: 
Thursday, March 14, 2024
Ovarian cancer, Immunotherapy, Patient, History, Lutetium (177Lu) oxodotreotide, IND, Cancer, NVS, NUVB, NCI, Novartis, Science, Colorectal cancer, Risk, American Cancer Society, FOLFIRINOX, PDAC, Pancreatic Cancer Action Network, Safety, Immune system, Interim, University, Translational research, Survival rate, Disease, Clinical professor, Associate, Tumor microenvironment, Death, TSX, Pancreatic cancer, Sunnybrook Health Sciences Centre, ACRS, FDA, DCP, Diagnosis, Entrepreneurship, Environment, Physician, Triple-negative breast cancer, Mortality, News, PROC, DDC, Hereditary nonpolyposis colorectal cancer, Optimism, ONC, Pharmaceutical industry

VANCOUVER, BC, March 14, 2024 /PRNewswire/ -- USA News Group - Known as one of the most deadly forms of cancer, pancreatic cancer still has the highest mortality rate of all major cancers today. However, researchers and the biotech sector are working diligently to improve the chances of those who receive this dire diagnosis. Recently, in late 2023, researchers at the Mayo Clinic made a discovery that advances knowledge of how pancreatic cancer spreads and identified a new potential therapeutic target along the way. With the American Cancer Society projecting a record year for new cancer cases in 2024, and Europe facing a pancreatic cancer emergency, it's important to focus on the advances being made in the biotech sector that are giving hope to patients and their families. Among the developers making gains include Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Novartis AG (NYSE: NVS), ImmunityBio, Inc. (NASDAQ: IBRX), Aclaris Therapeutics, Inc. (NASDAQ: ACRS), and Nuvation Bio Inc. (NYSE: NUVB). 

Key Points: 
  • There is a point of optimism to build upon, as the Pancreatic Cancer Action Network (PanCAN) has stated the five-year survival rate for pancreatic cancer has increased to 13% .
  • "Combining pelareorep with mFOLFIRINOX represents an expansion of our existing pancreatic cancer program and maximizes the potential of pelareorep-based combination therapies to benefit pancreatic cancer patients."
  • It will focus on patients with pancreatic cancer, HER2-negative metastatic breast cancer, metastatic castration-resistant prostate cancer (mCRPC), and platinum-resistant ovarian cancer (PROC).
  • Nuvation is already undergoing dosing in the Phase 1 monotherapy study of NUV-868 in solid tumors in patients with pancreatic cancer, ovarian cancer, metastatic castration-resistant prostate cancer (mCRPC), triple-negative breast cancer and other solid tumors.

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update

Retrieved on: 
Tuesday, February 27, 2024
Sun Pharma, Collection, MK2, Research, Eli Lilly and Company, ACRS, Atopic dermatitis, Health, Intangibles, Interim, IPR, Therapy, Rheumatoid arthritis, Patient, G&A, Pancreatic cancer, Pharmaceutical industry

Aclaris reported positive results from its Phase 1 MAD trial of ATI-2138 in September 2023.

Key Points: 
  • Aclaris reported positive results from its Phase 1 MAD trial of ATI-2138 in September 2023.
  • Net loss was $1.5 million for the fourth quarter of 2023 compared to $27.6 million for the fourth quarter of 2022.
  • Total revenue was $17.6 million for the fourth quarter of 2023 compared to $7.8 million for the fourth quarter of 2022.
  • Licensing expenses were $5.7 million for the quarter ended December 31, 2023 compared to $0.6 million for the prior year period.

The Inner Circle Acknowledges, Joshua Cohen as a Top Pinnacle Life Member

Retrieved on: 
Thursday, February 22, 2024
Philosophy, Eye, Inner circle, AAO, Multimedia, ACRS, Laser, Harvard University, BOCA, University, Mentorship, Patient, Family, Physician, Glaucoma

BOCA RATON, Fla., Feb. 22, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Joshua Cohen is acknowledged as a Top Pinnacle Life Member for his contributions to the field of Ophthalmology.

Key Points: 
  • BOCA RATON, Fla., Feb. 22, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Joshua Cohen is acknowledged as a Top Pinnacle Life Member for his contributions to the field of Ophthalmology.
  • Dr. Cohen pursued his prestigious education at Harvard University where he earned a Bachelor of Science degree.
  • He then attended the University of Gainesville where he received a Medical Doctor degree and completed residency at the University of Virginia.
  • Dr. Cohen is an expert in Lasik surgery, advanced cataract surgery, and glaucoma.

Aclaris Therapeutics Announces Leadership Changes and Strategic Business Review

Retrieved on: 
Tuesday, January 16, 2024
ACRS, Therapy, History, Comment, Interim, Disclosure, Atopic dermatitis, Concurrency, Pharmaceutical industry

WAYNE, Pa., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced leadership changes and that it is undertaking a strategic review of its business.

Key Points: 
  • to step down as Chief Executive Officer, President and Member of Board of Directors -
    WAYNE, Pa., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced leadership changes and that it is undertaking a strategic review of its business.
  • have mutually agreed that Dr. Manion will step down as Aclaris’ Chief Executive Officer and President and member of the Board of Directors, effective immediately.
  • Dr. Walker is a co-founder of Aclaris, has served as a member of the Board of Directors since its inception, and previously served as Aclaris’ Chief Executive Officer until 2022.
  • Aclaris also reiterates the following business plans:
    ATI-1777: Aclaris is seeking a development and commercialization partner for ATI-1777, its investigational topical “soft” JAK 1/3 inhibitor.

Aclaris Therapeutics Announces Top-line Results from 4-Week Phase 2b Trial of ATI-1777 for Mild to Severe Atopic Dermatitis

Retrieved on: 
Wednesday, January 10, 2024
ACRS, Patient, Therapy, Infection, Common, Malignancy, U.S. FDA, JAK, MACE, Aes, IC50, Plasma, Safety, Atopic dermatitis, BID, Clinical trial, Pharmacokinetics, QD, Pharmaceutical industry

WAYNE, Pa., Jan. 10, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced top-line results from its Phase 2b study of ATI-1777, an investigational topical “soft” JAK 1/3 inhibitor, in patients with mild to severe atopic dermatitis (AD) (ATI-1777-AD-202; NCT05432596). ATI-1777 was generated from Aclaris’ proprietary KINect® drug discovery platform.

Key Points: 
  • For this trial, ATI-1777 was developed as an emollient-containing spray formulation.
  • The trial randomized 250 patients with mild, moderate or severe AD, including adults and children as young as 12 years old, across 30 clinical trial sites in the United States.
  • “The trial demonstrated efficacy results, a pharmacokinetic profile and safety results that were consistent with what was seen in the Phase 2a trial of ATI-1777,” stated Dr. Neal Walker, Aclaris’ Chairman of the Board of Directors.
  • These results are particularly encouraging given the higher than anticipated vehicle response and the mid-study inclusion of a milder patient population.

Aclaris Therapeutics Provides Corporate Update

Retrieved on: 
Tuesday, December 19, 2023
Workforce, Atopic dermatitis, Osteoporosis, Therapy, Clinical trial, Pharmacokinetics, Kinect, Professional, MK2, Pancreatic cancer, Patient, Safety, ACRS, Ulcerative colitis, Pharmaceutical industry

WAYNE, Pa., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drugs for immuno-inflammatory diseases, today announced several corporate updates.

Key Points: 
  • WAYNE, Pa., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drugs for immuno-inflammatory diseases, today announced several corporate updates.
  • First, Aclaris announced the publication of the Phase 2a trial results of ATI-1777 in moderate to severe atopic dermatitis (AD) in the peer-reviewed journal JID Innovations on November 27, 2023.
  • Based on these results, Aclaris progressed ATI-1777 into a Phase 2b trial in patients with mild to severe AD.
  • Aclaris plans to use ATI-450 instead of ATI-2231, its second MK2 inhibitor, due to ATI-450’s more advanced clinical development package.

Aclaris Therapeutics Announces Patent License Agreement with Sun Pharma for Alopecia

Retrieved on: 
Tuesday, December 5, 2023
Sun Pharma, Alopecia areata, Therapy, Patent, Sun, Pattern hair loss, ACRS, AA, Generic drug

WAYNE, Pa., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drugs for immuno-inflammatory diseases, today announced an exclusive patent license agreement with Sun Pharmaceutical Industries, Inc. (Sun Pharma).

Key Points: 
  • WAYNE, Pa., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drugs for immuno-inflammatory diseases, today announced an exclusive patent license agreement with Sun Pharmaceutical Industries, Inc. (Sun Pharma).
  • Under the license agreement, Aclaris granted Sun Pharma exclusive rights under certain patents for the use of deuruxolitinib, Sun Pharma’s JAK inhibitor, or other isotopic forms of ruxolitinib, to treat alopecia areata (AA) or androgenetic alopecia (AGA).
  • Aclaris exclusively licenses the patents from a third party, and has separate contractual obligations under which it owes a portion of the consideration received from Sun Pharma.
  • “We are pleased to announce this patent license agreement with Sun Pharma, which represents our second out-license for this patent portfolio,” stated James Loerop, Chief Business Officer of Aclaris.

Aclaris Therapeutics Announces Top-line Results from 12-Week Phase 2b Trial of Oral Zunsemetinib (ATI-450) for Moderate to Severe Rheumatoid Arthritis and Provides Corporate Update

Retrieved on: 
Monday, November 13, 2023
Webcast, Pancreatic cancer, MK2, Safety, Therapy, Clinical trial, Patient, ACR20, Rheumatoid arthritis, ACRS, Pharmacokinetics, Ulcerative colitis, Atopic dermatitis, Topical medication, Toxic leukoencephalopathy, Osteoporosis, MTX, Pharmaceutical industry, Czech Republic

WAYNE, Pa., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drugs for immuno-inflammatory diseases, today announced top-line results from a Phase 2b study of zunsemetinib (ATI-450), an investigational oral MK2 inhibitor, in subjects with moderate to severe rheumatoid arthritis (RA; ATI-450-RA-202).

Key Points: 
  • The primary efficacy endpoint is the proportion of patients achieving an ACR20 response following 12 weeks of treatment.
  • Based on the overall program results, Aclaris will discontinue further development of the ATI-450 program, including halting enrollment of Aclaris’ ongoing Phase 2a trial of zunsemetinib in psoriatic arthritis.
  • “We are deeply disappointed with the results of this trial and for patients suffering from rheumatoid arthritis.
  • Aclaris is supporting Washington University in a first-in-human investigator-initiated Phase 1a trial of ATI-2231 in patients with advanced solid tumor malignancies.

The Inner Circle Acknowledges, Joshua Cohen as a Pinnacle Life Member for his contributions to the field of Ophthalmology

Retrieved on: 
Monday, November 13, 2023
Inner circle, University, Laser, University Auditorium (Gainesville, Florida), Physician, Patient, Multimedia, Eye, BOCA, AAO, ACRS, Mentorship, Family, Harvard University, Glaucoma, Philosophy, Ophthalmology

BOCA RATON, Fla., Nov. 13, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Joshua Cohen is acknowledged as a Top Pinnacle Life Member for his contributions to the field of Ophthalmology.

Key Points: 
  • BOCA RATON, Fla., Nov. 13, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Joshua Cohen is acknowledged as a Top Pinnacle Life Member for his contributions to the field of Ophthalmology.
  • Dr. Cohen pursued his prestigious education at Harvard University where he earned a Bachelor of Science degree.
  • He then attended the University of Gainesville where he received a Medical Doctor degree and completed residency at the University of Virginia.
  • Following a medical degree, he said that a doctor specializing in ophthalmology must pursue additional postgraduate residency training specific to that field.